Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395103 | 0.89 | GSK3B (0.48) | NPC1RAB9APTPN1CES1SMN1; SMN2 | |
| SCHEMBL11544329 | 0.82 | TTR (0.46) | NPC1RAB9APTPN1ALDH1A1LMNA | |
| SCHEMBL14918493 | 0.81 | TSHR (0.52) | CES2CES1SMN1; SMN2ALDH1A1CA1 | |
| SCHEMBL11770219 | 0.81 | CYP19A1 (0.57) | NPC1RAB9APTPN1CES2ALDH1A1 | |
| SCHEMBL7082902 | 0.81 | NPC1 (0.57) | NPC1RAB9APTPN1CES2CES1 | |
| SCHEMBL8610853 | 0.79 | CYP19A1 (0.51) | NPC1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL3659298 | 0.79 | TPMT (0.46) | CA1CA2MEN1KMT2AMAPT | |
| SCHEMBL1989864 | 0.79 | CES2 (0.54) | CES2CES1ALDH1A1 | |
| SCHEMBL1568921 | 0.79 | GSK3B (0.57) | NPC1RAB9ACES2CES1SMN1; SMN2 | |
| SCHEMBL135383 | 0.79 | GSK3B (0.55) | NPC1RAB9ACES2CES1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039300-A | Pyrazolopyrimidines Process for the preparation of the same | 上海信诺维生物医药有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-119039247-A | Preparation method of thiazole compound | 上海信诺维生物医药有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-115974721-B | Method for synthesizing 2-carbonyl substituted nitrile compound through 2, 2-trifluoroethyl ketone | 平顶山学院 | 2024-07-02 | — | — | CN | claimed |
| CN-115974721-A | Method for synthesizing 2-carbonyl substituted nitrile compound through 2,2,2-trifluoroethyl ketone | 平顶山学院 | 2023-04-18 | — | — | CN | claimed |
| CN-113527205-B | Preparation method of blonanserin intermediate | 湖南省湘中制药有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-110526867-B | Method for efficiently preparing blonanserin intermediate | 湖南省湘中制药有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-214514581-U | Reation kettle is used in preparation of high purity 4-fluorobenzoyl acetonitrile | 天津市科莱博瑞科技有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-113527205-A | Preparation method of blonanserin intermediate | 湖南省湘中制药有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-111233707-B | Synthesis and refining method of 4-fluorobenzoylacetonitrile | 南京远淑医药科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| CN-111233707-A | Synthesis and refining method of 4-fluorobenzoylacetonitrile | 南京远淑医药科技有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-105272883-B | A kind of preparation method of the fluoro benzoyl acetonitrile of high-purity 4 | 天津市科莱博瑞科技有限公司 | 2017-09-22 | — | — | CN | claimed |
| EP-0034270-A1 | Combinations of agents which give enhanced anti-inflammatory activity | AMERICAN CYANAMID COMPANY (US) | 1981-08-26 | — | — | EP | claimed |
| US-4083993-A | ARTHRITIS | AMERICAN CYANAMID CO. (US) | 1978-04-11 | — | — | US | claimed |
| US-20260102390-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARgamma AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2026-04-16 | — | — | US | disclosed |
| EP-4326274-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4637734-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARy AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2025-10-29 | — | — | EP | disclosed |
| US-4173650-A | ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1979-11-06 | — | — | US | disclosed |
| US-4083993-A | ARTHRITIS | AMERICAN CYANAMID CO. (US) | 1978-04-11 | — | — | US | disclosed |
| US-4083993-A | ARTHRITIS | AMERICAN CYANAMID CO. (US) | 1978-04-11 | — | — | US | disclosed |
| US-3951978-A | ANALGESIC, ANTIARRHYTHMIC, CENTRAL NERVOUS DEPRESSANT | ISTITUTO LUSO FARMACO D'ITALIA S.R.L. (IT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102390-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARgamma AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | PPARG, FABP1, PPARA | NPC1 1668/4885RAB9A 3277/4885PTPN1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.